Trials / Completed
CompletedNCT00549692
Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy
Minimization, Double-blind, Placebo-controlled, Multi-center, Phase 3 Study to Evaluate the Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of IgA Nephropathy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 152 (actual)
- Sponsor
- Kuhnil Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare omega-3 fatty acids with placebo for efficacy in retardation of increase of serum creatinine(SCr) in IgA Nephropathy
Detailed description
In the current clinical study, attempts are made to assess the safety and efficacy of omega-3 fatty acids by comparing between omega-3 fatty acids and the placebo in Korean patients with IgA nephropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Omega-3 fatty acid ethylester90 | Dosage form :1g soft capsule Dosage : two capsules, twice a day. |
Timeline
- Start date
- 2007-11-01
- Primary completion
- 2012-08-01
- Completion
- 2012-09-01
- First posted
- 2007-10-26
- Last updated
- 2012-09-27
Locations
5 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT00549692. Inclusion in this directory is not an endorsement.